chrisvoncsefalvay/vaers-outcomes huggingface dataset:
RIGHT AFTER VACCINATED, PATIENTS START TO PRESENT A SEVERE RASH IN HER BODY, AND HER EYES WERE VERY RED. PATIENTS DID NOT SHOW ANY SIGH OF SWELLING AND WAS ABLE TO BREATH. AFTER REASSES OF THE SITUATUION, PROCEED TO INJECT DIPHENHYDRAMINE 50MG/ML VIAL. PROCEED TO CALL 911, WHEN THE PARAMEDICS ARRIVED, VITAL SIGNS WERE TAKEN. AFTER 15 MINUTES OF THE ADMINISTRATION ALL RASH AND RED IN HER SKIN STARTED TO IMPROVISED. PATIENTS WAS OBSERVED FOR 30 MORE MINUTES AND THE PARAMEDICS PROCEED TO DISCHARGE HER HOME.
02/16/2022, I had my blood work done and I had 3 things that are out of range that my entire life has never been out of range before. Alkaline phosphate- 128 - it was high, T-3 uptake - 18 - was low,  Free thyroxine index- 1.1  - which is low.  The doctor would like to have it my blood work retaken in 3 months. I had never had any of these abnormalities before, my diet has not changed, my medications have not changed in the last 10 years. No treatment at this time.
sore lt arm 1st few days;then enlargement, swelling, & pain to 5x10cm erythema, ache-center firm, tender, hematoma over total of 5 days;hematoma secondary to cellulitis;
This spontaneous report as received from a 61 year old female patient reporting on herself. The patient's pertinent medical history, drug reactions/allergies were not provided. On 20-NOV-2014, the patient was vaccinated with a dose of ZOSTAVAX (route, dose, lot # and expiration date were not provided). Co-suspect therapies and concomitant medications were not provided. On 25-NOV-2014, reported as time of the report, the patient had a bump on her neck. The patient did not seek medical attention but she stated that she will call her doctor. At the time of the report, the patient's outcome and the relatedness between the event and suspect therapy were not provided. Additional information is not expected since no contact information was provided.
pt recv vax 14JUL98 & was cranky, would not allow legs to be touched;18JUL98 devel one raised, red spot w/center vesicle @ site of varicella shot;25JUL98 devel red welts w/o papule centers;28JUL98 devel lesions on rt leg near shin bone;pus
Information has been received from a RN via a company representative concerning a 25 year old male pt with no medical history who on 15Aug1979 (previously reported as 28Apr1980) was vaccinated with a dose of measles virus vaccine live  (Moraten) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3). He received another dose of measles virus vaccine live  (Moraten) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3)  on 15Jun1991 (previously reported as 14Jun1996). On 15Jul03 the pt developed the following symptoms and went to the ER; fever of 103 degrees, testicular pain for 2 weeks, vomiting, nausea, headache, cough and bilateral parotitis. A rapid strep test in the ER was negative. Through urine testing and a throat culture on 18Jul2003, mumps strain was verified. The bilateral parotis lasted for 5 days. The pt was not hospitalizes; he was treated with antibiotics and recovered on 25Jul2003. In follow up information it was noted that the pt has had no adverse events following prior vaccination. Additional information is not expected.
ACUTE PULMONARY EMBOLISM 3/31/2023 ACUTE PULMONARY EMBOLISM ACUTE DVT OF RIGHT LEG, UNSPECIFIED VEIN 3/28/2023 ACUTE PULMONARY EMBOLISM ACUTE DVT OF BILAT FEMORAL VEINS 3/31/2023 ACUTE PULMONARY EMBOLISM ACUTE PULMONARY EMBOLISM 3/31/2023 EPISTAXIS ACUTE DVT OF RIGHT LEG, UNSPECIFIED VEIN 3/28/2023 EPISTAXIS ACUTE DVT OF BILAT FEMORAL VEINS 3/31/2023 EPISTAXIS
p/ pt recv vax approx 3 days later pt exp breakthrough chickenpox w/less than 10 discrete papulopustules. rpt felt breakthrough not related to therapy w/varicella, varicella virus was stored in refrigerator.
Pains throughout the entire body; This is a spontaneous report from a contactable consumer (patient). A 55-year-old patient of an unspecified gender received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number: EL9269), via an unspecified route of administration in left arm on 03Feb2021 at 11:30 AM as single dose for COVID-19 immunisation. Medical history included atrial fibrillation and hypertension. Concomitant medications included nebivolol hydrochloride (BYSTOLIC) at 10 mg and doxycycline (ORACEA) at 40 mg. The patient did not have allergies to medications, food, or other products. The patient did not received any other vaccine within 4 weeks prior to the COVID vaccine. Reportedly, patient was not diagnosed with COVID-19 prior to vaccination. Patient had not been tested for COVID-19 since the vaccination. On 05Feb2021 at 09:00 PM, patient had pains throughout the entire body starting two days after vaccine was given. First pain was in lower left calf; sharp pain. Had experienced pains though out my entire body one and off since (10Feb). The patient was visited emergency room. No treatment was received for the adverse event. The outcome of the event was recovering.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 85-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 19Jan2021 at 14:00 as dose 1, single (Lot number: EL3249), in left arm, in Feb2021 as dose 2, single (Lot number: EL9269), in left arm, on 30Sep2021 at 12:00 as dose 3 (booster), single (Lot number: FF8839), in left arm and on 04May2022 at 11:00 as dose 4 (booster), single (Lot number: FP1554) at the age of 84 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "On blood pressure meds" (unspecified if ongoing); "cpap" (unspecified if ongoing); "have restless leg syndrome" (unspecified if ongoing). No known allergies. Concomitant medication(s) included: GABAPENTIN, start date: 16Jun2014, stop date: 17Aug2022; LEVOTHYROXINE, start date: Jan2000, stop date: Aug2022; AMLODIPINE, start date: Jan2002, stop date: Aug2022; PRAMIPEXOLE, start date: Jan2002, stop date: 17Aug2022; METOPROLOL, start date: Jan2005, stop date: Aug2022. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (2022) Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19.
Severe arm pain. Pain was so severe that I could not move it for 24 hours and pain was severe for 3 days. Today is day 6 and it is still sore and feel hot when moved. Fever of 100.5 for 12 hours and heart rate between 104 - 111 while lying down.
Area of 6" long by 4" under from deltoid muscle on R upper arm down with redness, raised blotching, warm to touch, soreness. ROM - good. C/O pain when moving temp 98.3. 10/30/09 - pt had recovered she states.
Information has been received from a physician concerning an elderly male patient with a pertinent medical history ( no details provided) who on Jul 20 2004 was vaccinated with pneumococcal 23v polysaccharide vaccine (lot 646322/0530N). Subsequently, the patient developed a red, swollen arm at injection site, Medical attention was sought. Ice and analgesic treatment was reported. The reporting physician requested a lot check. No product quality complaint. The records of testing prior to release of this lot have been checked by Quality Assurance and found to be satisfactory, The lot complies with the standards of the Center for Biologics Evaluation and Research and was released. It was reported that two other patients had a similar reaction (WAES0407USA01800, WAES0407USA02326). Additional information has been requested.
Caller returning call with patient information regarding improperly stored vaccine administration; No additional AE; This spontaneous report was received from an unspecified reporter (reported as "other"), referring to a patient of unknown age and gender. The patients' pertinent medical history, current conditions, previous drug reactions or allergies and concomitant medications were not reported.   On an unknown date, the patient was vaccinated with an improperly stored of varicella virus vaccine live (oka/merck) (VARIVAX), admisitered at a dose of 0.5 milliliters (ml) (formulation, strength, vaccination scheme, route of administration and anatomical site of vaccination were not reported; lot number S038702, which has been verified to be valid, expiration date reported and validated as 01-DEC-2021) as prophylaxis. The vaccine administered experienced a temperature of -9.5 degrees Celsius (C) for 8 hours and 53 minutes; and -10.1C for 6 hours and 40 minutes, as recorded by a data logger. There was no previous temperature excursion reported. No additional adverse event were reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2009USA008353: US-009507513-2009USA008520:
sz lasted over 1hr, pt posturing 19OCT96 pt began having grand mal sz an ambulance was called;pt arrived @ hosp vitals: t101.4 R, pulse 172, resp 28, Sat 02 88%, IV access required w/IO;APAP rectal, dilantin;CT, LP
On 10-2-13 pt reported after receiving pre exposure rabies on 4/12/13 - she developed rash overnight.
Since 7-15-2016 I experienced pain and weakness in joints and ankles, and difficulty walking. This progressed over the next few months into sever pain and weakness in the ankles, knee, toes, elbow, wrist and fingers. Sometimes including pain in my face. I was unable to walk without a cane. I was unable to open a car door. I fell 2/2017 and broke my wrist. 04/30/2017 I fell and broke L1 vertebrae. These falls were sudden and without reason except my ankles gave out. Physically therapy was conducted for my wrist, back and ankle stability between March and December 2017. My wrist and back improved, however ankle stability has not improved. To this day I cannot but on a pair of pants without leaning against a support. I cannot walk a set of stairs without a railing.  Sometimes my wrists give out without notice causing me to drop items. I cannot stand for more than 5 minutes without sitting. This constant pain and weakness continues to this date.
This case was reported by a pharmacist via call center representative and described the occurrence of fever in a 55-year-old female patient who received SHINGRIX (batch number 49R72, expiry date 13th January 2021) for prophylaxis. This case was associated with a product complaint. On 9th January 2019, the patient received the 2nd dose of SHINGRIX (intramuscular) .5 ml. On 9th January 2019, less than a day after receiving SHINGRIX, the patient experienced injection site erythema. In January 2019, the patient experienced fever, welts, rash, general body pain and influenza-like symptoms. On an unknown date, the patient experienced pharmaceutical product complaint. On an unknown date, the outcome of the fever, welts, rash, general body pain, injection site erythema and influenza-like symptoms were recovered/resolved and the outcome of the pharmaceutical product complaint was unknown. It was unknown if the reporter considered the fever, welts, rash, general body pain, injection site erythema and influenza-like symptoms to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX vaccine in the left deltoid. The patient had defined red ring around the injection site that started the evening after receiving vaccine. Less than a week after receiving vaccination, the patient had a fever and body temperature was recorded as  102 degrees F.  The patient developed whelps and a rash that went up and down her arm. The patient hurt all over her body like she had the flu. All symptoms resolved after three days. The reporter did not consent to follow up. This case was 3 of 4 cases reported.
Information has been requested from a healthcare professional concerning a pt who on approx. 6/9/00 was vaccinated with 1 dose of pneumococcal vaccine 23 polyvalent (lot 633103/1216J). Subsequently, the pt experienced cellulitis at the injection site that extended all the way down the arm. The pt was treated with antibiotics in the ER but not admitted. Another pt (WAES 00062248) had a similar experience. Additional information has been requested.
66 days outside of his first dose; This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (66 days outside of his first dose) in a 23-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (66 days outside of his first dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (66 days outside of his first dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.; Sender's Comments: This report refers to a case of Inappropriate Schedule Of Product Administration for mRNA-1273 (Lot number: Unknown) with no associated adverse events.
TWO LUMPS ON LEFT SIDE OF NECK; ITCHINESS; PAIN; FATIGUE; FELT FEVER; CHILLS; MILD MUSCLE ACHES; This spontaneous report received from a patient concerned a 35 year old male. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A expiry: 21-JUNE-2021) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 10-APR-2021, the subject experienced chills. On 10-APR-2021, the subject experienced mild muscle aches. On 10-APR-2021, the subject experienced felt fever. Treatment medications included: paracetamol. On 11-APR-2021, the subject experienced fatigue. On 13-APR-2021, the subject experienced two lumps on left side of neck. On 13-APR-2021, the subject experienced itchiness. On 13-APR-2021, the subject experienced pain. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from chills, mild muscle aches, and felt fever on 11-APR-2021, and fatigue on 13-APR-2021, had not recovered from two lumps on left side of neck, and the outcome of pain and itchiness was not reported. This report was non-serious.
Chest pain, pressure over 2 day period. Patient seen in clinic and ER. EKG normal, troponin elevated. Normal CT scan. Diagnosed pericarditis secondary to small pox vaccine. Pericarditis, elevated liver function test. 5/4/06 Received medical records which revealed Dx: myocarditis & pericarditis/ss
Evening of 9/24/21 developed fever, fatigue and dyspnea. Symptoms worsened so went to ED on 9/27/2021, was hypoxic to 83% on room air, chest x-ray showed signs of multifocal pneumonia/ARDS; sepsis orders initiated. Admitted in the setting of acute respiratory failure/ARDS/multifocal pneumonia; condition worsened and ended up in ICU; developed acute renal failure during hospitalization. Was discharged on 10/8/2021.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 64-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 19Jan2022 as dose 4 (booster), single (Lot number: FJ1614), in left arm and on 14Feb2022 as dose 5 (booster), single (Lot number: FM0698) at the age of 63 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 03Mar2021 at 16:45 as dose 1, single (Batch/Lot number: unknown), in left arm, on 31Mar2021 at 10:00 as dose 2, single (Batch/Lot number: unknown), in left arm and on 21Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Pulmonary Amyloidosis" (unspecified if ongoing); "Sjogren's syndrome" (unspecified if ongoing); "interstitial lung disease" (unspecified if ongoing); "ADHD" (unspecified if ongoing); "Lung cancer" (unspecified if ongoing); "Interchange of vaccine products" (unspecified if ongoing). Concomitant medication(s) included: EVUSHELD, on 19Apr2022; PREDNISONE, start date: Apr2022; ADVIL [IBUPROFEN], start date: Jan2022. Past drug history included: Biaxin, reaction(s): "Known allergies: Biaxin"; Metoprolol, reaction(s): "Known allergies: metoprolol"; Molnuparavir, reaction(s): "Known allergies: molnuparavir"; Amoxicillin, reaction(s): "Known allergies: amoxicillin"; Omeprazole, start date: Apr2011; Vyvanse, start date: Jan2018; Effexor, start date: Sep2016; Fluticasone, start date: May2017; Cevemeline, start date: May2010; Vitamin d, start date: Jan2016; Advil, start date: Jan2022; Prednisone, start date: Apr2022. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: COVID 19 Treatment; (Jul2022) Positive, notes: still testing positive. Therapeutic measures were taken as a result of drug ineffective, covid-19.
This spontaneous report was received from a nurse, who referred to multiple patients of unknown demographics. No information regarding the patients' pertinent medical history, concomitant therapies and drug reactions or allergies was provided. On unknown dates, the patients were vaccinated with improperly stored doses of VAQTA (lot# M038572 and expiration date: 11-MAR-2018, lot# M047658 and expiration date: 28-OCT-2017; dose, route of administration and anatomical location were not reported) for prophylaxis. The vaccine underwent the temperature excursion of more than 47 Fahrenheit degrees (F) but less than 77 F for 4 hours, which was detected by a data logger. No previous temperature excursions were reported. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of four reports received from the same reporter. Additional information has been requested.; Sender's Comments:  US-009507513-1705USA015585: US-009507513-1706USA002227: US-009507513-1706USA002228:
Admission diagnoses: Febrile illness, dehydration, N/V, DM. Discharge diagnoses: fever of unknown origin, ARF, severe CAD, DM, S/P pulmonary edema and respiratory failure, S/P episode of ICU psychoses with polyneuropathy. The patient was a 45 year old male S/P catheterization on 3/16/04. He also received a pneumococcal vaccine the same day. He was discharged the next day, and had a few chills throughout the day on 3/17/04, as well as into the night, and awoke on 3/18/04 with a HA, nausea, low back pain, diaphoresis, feeling cold, and a temp of 101 degrees. He called his cardiologist, and was told to come into the Emergency Department. On day 2 of admission, the patient had a dramatic cellulitic response and swelling on the right deltoid area where he received the Pneumovax, and it was believed that this was the reason for his fever. Infectious disease was consulted. Fever was resolved with empiric ATB treatment and cellulitis improved. The patient was switched to cephalexin and was afebrile for 36 hours, and then spiking a fever to a high of 103.2 degrees. On hospital admission day 5, the patient got increasingly short of breath that did not resolve with IV Lasix and required intubation and transfer to the ICU/CCU area. Pulmonology service was consulted. The patient required vent management for approximately 6 days. It was believed that respiratory failure was secondary to severe pulmonary edema. The patient was discharged on 4/3/04. Physicians felt this was a reaction to the vaccine.
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 59-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 23Jan2022 at 11:00 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 59 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Diabetes" (unspecified if ongoing); "high blood pressure" (unspecified if ongoing); "obesity" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant) all with onset Jul2022, outcome "not recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) negative; (23Jul2022) positive. Therapeutic measures were taken as a result of covid-19, drug ineffective. Clinical course: After testing negative patient started feeling sick again. Worse then original. Tested positive. Proprietary medicinal product name: Pavloxid, Indication for use in the case: Treatment of COVID-19, Date of start of drug: 15Jul2022, Date of last administration: 19Jul2022, The patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment. The patient previously received a COVID-19 Vaccine.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Father reports swollen area in groin above injection sites in both legs. Child has no fever and is eating and drinking as usual. Reported on 4/18/2000, vaccine administered on 4/11/00. Advised by Health Department nurse to see family physician. Father reports that physician said swollen glands were a reaction to vax.
Covid breakthrough. It started that Saturday evening, I was feeling fatigued and a little bit of a scratchy throat. For the next five days I was pretty much bed ridden. I had chills, sweats and body aches. I also had a headache for the first few days. I also had a runny nose, sore throat, congestion, and cough.
The next day I woke up to my right arm swollen, hot, and feels like an orange peel. It's been over 48 hours and the swelling is not going down. It really doesn't hurt at all. It's very numb so it's easy for me to ice it, because I can't feel it.
Systemic: Abdominal Pain-Medium, Systemic: Nausea-Medium, Systemic: Vomiting-Medium, Additional Details: patient vomiting within minutes of receiving injection
Patient complained of dizziness after receiving vaccination at 7:45. Patient did not eat breakfast. She was slightly hypotensive and was given a snack and water. Patient still feeling light-headed at 8:00, however stated this is common for her. At 8:23, she reported feeling better.
About 24 hrs after shot (Tdap) noticed swollen red area at site of injection. Achy body, arms and legs. Increased redness to 90 mm x 130 mm when seen in clinic 8-12-11. No fever. Pt stated he was dizzy. At site of MMR 35 mm x 40 mm redness when seen at clinic 8-12-11. Pt states area feeling better today 8-12-11.
Day following vaccine severe bladder + urethra pain. Had been treated for UTI, treatment was successful + symptoms minimal or gone. Ran urine tests with 4 labs and found over growth of bacteria that was not causing ant prior problem. The bacteria found was Citrobacter Koseri at >100,000 cfu/ml All previous pathogens, based on new labs are gone. I believe it's possible that the vaccine affected my body's immune system and its ability to deal with an infection that was minimized  + managed. I'm not immune comprimezed, I'm not taking immuno-suppresant drugs and yet Four days after the 2nd  Pfizer vaccine I experienced severe urinary pain and had to resort to get advice from physicians  and start on antibiotic treatment. The conclusion is I think the vaccine affected  my immune system.